Alnylam’s patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac – Endpoints News
FierceBiotech |
Alnylam’s patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac
Endpoints News CRISPR Therapeutics, together with its joint venture Casebia, is teaming up with CureVac to develop improved Cas9 mRNA constructs for in vivo gene editing. CureVac will also take charge of manufacturing all mRNA needed in clinical development and … BRIEF—New mRNA collaboration for CRISPR, Casebia and CureVacThe Pharma Letter |
Scope (blog) |
In study inspired by late Stanford physician, immunotherapy found safe in HIV patients
Scope (blog) And the findings — that it is safe for people with HIV and cancer to receive a type of cancer immunotherapy called a checkpoint inhibitor — are just what Kohrt would have predicted, the study’s senior author Martin “Mac” Cheever, MD, explained in a … |